Summary of the clinical information of the KURAMA and the IORRA cohort at baseline.
| Characteristics | Set 1 (KURAMA) | Set 2 (IORRA) |
|---|---|---|
| No. subjects (cases and controls) | 490 vs 500 | 2383 vs 1508 |
| Case characteristics | ||
| Female ratio, % | 75.71 | 85.78 |
| Age, yrs, mean ± SD | 57.3 ± 13.7 | 58.5 ± 15.0 |
| RF-positive, % | 85.1 | 88.6 |
| No. RF data for each subject, mean ± SD | 51.7 ± 33.5 | 14.4 ± 6.7 |
| RF level, IU/ml, mean ± SD | 538.56 ± 1852.40 | 326.35 ± 564.84 |
| RF category (constant RF+/seroconversion/constant RF−), n | 216/184/73 | 1156/786/271 |
| CCP-positive, % | 76.0 | 81.2 |
| CCP level, U/ml, mean ± SD | 193.26 ± 242.15 | 154.91 ± 275.97 |
KURAMA: Kyoto University Rheumatoid Arthritis Management Alliance; IORRA: Institute of Rheumatology, Rheumatoid Arthritis; RF: rheumatoid factor; CCP: cyclic citrullinated peptide.